Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

Fig. 5

Combined blockade of IL-6 and PD-L1 elicits synergistic antitumor immune responses in a murine model of LUSC. A Schemas for constructing the murine model of LUSC and dosing schedule. B Mice bearing KLN205 cells (n = 5) were treated with paclitaxel, anti-IL-6 mAb, and anti-PD-L1 mAb, according to the dosing schedule. Control mice were treated with isotype control. Anti-PD-L1 mAb combined with anti-IL-6 mAb or paclitaxel significantly reduced tumor growth in mice with lung adenocarcinomas. C Representative illustrations of tumor nodules in each treated group. D–H The distributions and representative IHC images of PD-L1 expression (D), CD8+ T cells (E), M2 macrophages (F), Treg cells (G), and MDSCs (H) in each treated group. Scale bar = 20 μm. ns: P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page